Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company that’s developing cancer-killing drugs, announced it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.
The Natick-based company said the number of shares to be offered and the price range have yet to be determined.
Karyopharm is pursuing new treatments that return displaced proteins to the nuclei of affected cells, where they can audit the cells for damage in cases where cancer had disabled this process.
The company said it is pursuing both human and veterinary applications, however bringing the drug to market is still likely years away. In May, Karyopharm said it raised $48.2 million in Series B financing, which will be used to bring its lead drug, KPT-330, through full clinical development.
Read more
